{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:42:32Z","timestamp":1715992952024},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,17]]},"DOI":"10.7759\/cureus.60476","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:50:26Z","timestamp":1715935826000},"source":"Crossref","is-referenced-by-count":0,"title":["The Dilemma of Balancing Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-\u03b1) Biologics for Psoriatic Arthritis Control With the Risk of Severe Systemic Infection"],"prefix":"10.7759","author":[{"given":"Yi-Fan","family":"Mai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Cheng","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Tsai","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020719","article-title":"TNFalpha therapy in psoriatic arthritis and psoriasis","volume":"63","author":"Mease P","year":"2004","unstructured":"Mease P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis. 2004, 63:755-8. 10.1136\/ard.2004.020719","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","volume":"33","author":"Davis JS","year":"2020","unstructured":"Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. 2020, 33:10.1128\/CMR.00035-19","journal-title":"Clin Microbiol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1615\/critreveukargeneexpr.v20.i2.10","article-title":"Tumor necrosis factor-\u03b1 signaling in macrophages","volume":"20","author":"Parameswaran N","year":"2010","unstructured":"Parameswaran N, Patial S. Tumor necrosis factor-\u03b1 signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010, 20:87-103. 10.1615\/critreveukargeneexpr.v20.i2.10","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic I","year":"2010","unstructured":"Solovic I, Sester M, Gomez-Reino JJ, et al.. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010, 36:1185-206. 10.1183\/09031936.00028510","journal-title":"Eur Respir J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005699","article-title":"Tnf\u03b1 impairs Rhabdoviral clearance by inhibiting the host autophagic antiviral response","volume":"12","author":"Esp\u00edn-Palaz\u00f3n R","year":"2016","unstructured":"Esp\u00edn-Palaz\u00f3n R, Mart\u00ednez-L\u00f3pez A, Roca FJ, et al.. Tnf\u03b1 impairs Rhabdoviral clearance by inhibiting the host autophagic antiviral response. PLoS Pathog. 2016, 12:e1005699. 10.1371\/journal.ppat.1005699","journal-title":"PLoS Pathog"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali T","year":"2013","unstructured":"Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013, 5:79-99. 10.2147\/DHPS.S28801","journal-title":"Drug Healthc Patient Saf"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.01.014","article-title":"Anti-TNF therapy induced immune neutropenia in Crohns disease- report of 2 cases and review of literature","volume":"6","author":"Sebastian S","year":"2012","unstructured":"Sebastian S, Ashton K, Houston Y, Diggory TM, Dore P. Anti-TNF therapy induced immune neutropenia in Crohns disease- report of 2 cases and review of literature. J Crohns Colitis. 2012, 6:713-6. 10.1016\/j.crohns.2012.01.014","journal-title":"J Crohns Colitis"},{"key":"ref8","article-title":"Tumor Necrosis Factor Inhibitors","author":"Gerriets V","year":"2024","unstructured":"Gerriets V, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. StatPearls [Internet], Treasure Island (FL); 2024."},{"key":"ref9","article-title":"Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment","volume":"59","author":"Nordgaard-Lassen I","year":"2012","unstructured":"Nordgaard-Lassen I, Dahlerup JF, Belard E, Theede K, Tjellesen L. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012, 59:4480.","journal-title":"Dan Med J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120252","article-title":"Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-\u03b1 blockers for psoriatic arthritis","volume":"89","author":"Sanduzzi A","year":"2012","unstructured":"Sanduzzi A, Bocchino M, Atteno M, et al.. Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-\u03b1 blockers for psoriatic arthritis. J Rheumatol Suppl. 2012, 89:82-5. 10.3899\/jrheum.120252","journal-title":"J Rheumatol Suppl"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis GE","year":"2023","unstructured":"Fragoulis GE, Nikiphorou E, Dey M, et al.. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023, 82:742-53. 10.1136\/ard-2022-223335","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000001735","article-title":"Clinical significance of pro-inflammatory cytokines and their correlation with disease severity and blood coagulation in septic patients with bacterial co-infection","volume":"56","author":"Wang X","year":"2021","unstructured":"Wang X, Zhang Q, Yan Y, Yang Y, Shang X, Li Y. Clinical significance of pro-inflammatory cytokines and their correlation with disease severity and blood coagulation in septic patients with bacterial co-infection. Shock. 2021, 56:396-402. 10.1097\/SHK.0000000000001735","journal-title":"Shock"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex049","article-title":"Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis","volume":"57","author":"Lee WJ","year":"2018","unstructured":"Lee WJ, Lee TA, Suda KJ, Calip GS, Briars L, Schumock GT. Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis. Rheumatology (Oxford). 2018, 57:273-82. 10.1093\/rheumatology\/kex049","journal-title":"Rheumatology (Oxford)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes IB","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, et al.. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021, 384:1227-39. 10.1056\/NEJMoa2022516","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/252312-the-dilemma-of-balancing-anti-tumor-necrosis-factor-alpha-anti-tnf--biologics-for-psoriatic-arthritis-control-with-the-risk-of-severe-systemic-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:50:30Z","timestamp":1715935830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/252312-the-dilemma-of-balancing-anti-tumor-necrosis-factor-alpha-anti-tnf--biologics-for-psoriatic-arthritis-control-with-the-risk-of-severe-systemic-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.60476","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,17]]}}}